1-3 of 3
drug administration routes
Close
Sort by
Journal Articles

Additional chromosomal abnormalities at chronic myeloid leukemia diagnosis predict an increased risk of progression

Clinical Trials & Observations
Richard E. Clark, Jane F. Apperley, Mhairi Copland, Silvia Cicconi
Journal: Blood Advances
Blood Adv (2021) 5 (4): 1102–1109.
https://doi.org/10.1182/bloodadvances.2020003570
Published: 2021
Includes: Supplemental data
Journal Articles

Mesenchymal stromal cell therapeutic potency is dependent upon viability, route of delivery, and immune match

Jayeeta Giri, Jacques Galipeau
Journal: Blood Advances
Blood Adv (2020) 4 (9): 1987–1997.
https://doi.org/10.1182/bloodadvances.2020001711
Published: 2020
Includes: Supplemental data
Journal Articles

Therapeutic efficacy of the platelet glycoprotein Ib antagonist anfibatide in murine models of thrombotic thrombocytopenic purpura

Liang Zheng, Yingying Mao, Mohammad S. Abdelgawwad, Nicole K. Kocher, Mandy Li, Xiangrong Dai, Benjamin Li, X. Long Zheng
Journal: Blood Advances
Blood Adv (2016) 1 (1): 75–83.
https://doi.org/10.1182/bloodadvances.2016000711
Published: 2016
Includes: Multimedia, Supplemental data